In the context of hepatocellular carcinoma (HCC) treatment, Zhang et al. [29] developed NPs based on Cs conjugated to β-galactose carrying lactobionic acid (La), which specifically targets HCC cells expressing the asialoglycoprotein receptor (ASGPR) on their cellular membrane (Figure 6B) [30]. The gene discussed is ASGR1; the disease is hepatocellular carcinoma.